AARC clinical practice guideline. Surfactant replacement therapy: 2013

Brian K. Walsh, Brandon Daigle, Robert M. DiBlasi, Ruben D. Restrepo

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

We searched the MEDLINE, CINAHL, and Cochrane Library databases for English-language randomized controlled trials, systematic reviews, and articles investigating surfactant replacement therapy published between January 1990 and July 2012. By inspection of titles, references having no relevance to the clinical practice guideline were eliminated. The update of this clinical practice guideline is based on 253 clinical trials and systematic reviews, and 12 articles investigating surfactant replacement therapy. The following recommendations are made following the Grading of Recommendations Assessment, Development, and Evaluation scoring system: 1: Administration of surfactant replacement therapy is strongly recommended in a clinical setting where properly trained personnel and equipment for intubation and resuscitation are readily available. 2: Prophylactic surfactant administration is recommended for neonatal respiratory distress syndrome (RDS) in which surfactant deficiency is suspected. 3: Rescue or therapeutic administration of surfactant after the initiation of mechanical ventilation in infants with clinically confirmed RDS is strongly recommended. 4: A multiple surfactant dose strategy is recommended over a single dose strategy. 5: Natural exogenous surfactant preparations are recommended over laboratory derived synthetic suspensions at this time. 6: We suggest that aerosolized delivery of surfactant not be utilized at this time.

Original languageEnglish (US)
Pages (from-to)367-375
Number of pages9
JournalRespiratory Care
Volume58
Issue number2
DOIs
StatePublished - Jan 1 2013

Fingerprint

Practice Guidelines
Surface-Active Agents
Therapeutics
Newborn Respiratory Distress Syndrome
Artificial Respiration
Intubation
Resuscitation
MEDLINE
Libraries
Suspensions
Language
Randomized Controlled Trials
Clinical Trials
Databases
Equipment and Supplies

Keywords

  • Exogenous surfactant administration
  • Intratracheal administration
  • Neonatal respiratory distress syndrome
  • Prematurity
  • Surfactant

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine
  • Critical Care and Intensive Care Medicine

Cite this

Walsh, B. K., Daigle, B., DiBlasi, R. M., & Restrepo, R. D. (2013). AARC clinical practice guideline. Surfactant replacement therapy: 2013. Respiratory Care, 58(2), 367-375. https://doi.org/10.4187/respcare.02189

AARC clinical practice guideline. Surfactant replacement therapy : 2013. / Walsh, Brian K.; Daigle, Brandon; DiBlasi, Robert M.; Restrepo, Ruben D.

In: Respiratory Care, Vol. 58, No. 2, 01.01.2013, p. 367-375.

Research output: Contribution to journalArticle

Walsh, BK, Daigle, B, DiBlasi, RM & Restrepo, RD 2013, 'AARC clinical practice guideline. Surfactant replacement therapy: 2013', Respiratory Care, vol. 58, no. 2, pp. 367-375. https://doi.org/10.4187/respcare.02189
Walsh, Brian K. ; Daigle, Brandon ; DiBlasi, Robert M. ; Restrepo, Ruben D. / AARC clinical practice guideline. Surfactant replacement therapy : 2013. In: Respiratory Care. 2013 ; Vol. 58, No. 2. pp. 367-375.
@article{e2491bc746ea43f3867fc69e6cc4c8ca,
title = "AARC clinical practice guideline. Surfactant replacement therapy: 2013",
abstract = "We searched the MEDLINE, CINAHL, and Cochrane Library databases for English-language randomized controlled trials, systematic reviews, and articles investigating surfactant replacement therapy published between January 1990 and July 2012. By inspection of titles, references having no relevance to the clinical practice guideline were eliminated. The update of this clinical practice guideline is based on 253 clinical trials and systematic reviews, and 12 articles investigating surfactant replacement therapy. The following recommendations are made following the Grading of Recommendations Assessment, Development, and Evaluation scoring system: 1: Administration of surfactant replacement therapy is strongly recommended in a clinical setting where properly trained personnel and equipment for intubation and resuscitation are readily available. 2: Prophylactic surfactant administration is recommended for neonatal respiratory distress syndrome (RDS) in which surfactant deficiency is suspected. 3: Rescue or therapeutic administration of surfactant after the initiation of mechanical ventilation in infants with clinically confirmed RDS is strongly recommended. 4: A multiple surfactant dose strategy is recommended over a single dose strategy. 5: Natural exogenous surfactant preparations are recommended over laboratory derived synthetic suspensions at this time. 6: We suggest that aerosolized delivery of surfactant not be utilized at this time.",
keywords = "Exogenous surfactant administration, Intratracheal administration, Neonatal respiratory distress syndrome, Prematurity, Surfactant",
author = "Walsh, {Brian K.} and Brandon Daigle and DiBlasi, {Robert M.} and Restrepo, {Ruben D.}",
year = "2013",
month = "1",
day = "1",
doi = "10.4187/respcare.02189",
language = "English (US)",
volume = "58",
pages = "367--375",
journal = "Respiratory Care",
issn = "0020-1324",
publisher = "Daedalus Enterprises Inc.",
number = "2",

}

TY - JOUR

T1 - AARC clinical practice guideline. Surfactant replacement therapy

T2 - 2013

AU - Walsh, Brian K.

AU - Daigle, Brandon

AU - DiBlasi, Robert M.

AU - Restrepo, Ruben D.

PY - 2013/1/1

Y1 - 2013/1/1

N2 - We searched the MEDLINE, CINAHL, and Cochrane Library databases for English-language randomized controlled trials, systematic reviews, and articles investigating surfactant replacement therapy published between January 1990 and July 2012. By inspection of titles, references having no relevance to the clinical practice guideline were eliminated. The update of this clinical practice guideline is based on 253 clinical trials and systematic reviews, and 12 articles investigating surfactant replacement therapy. The following recommendations are made following the Grading of Recommendations Assessment, Development, and Evaluation scoring system: 1: Administration of surfactant replacement therapy is strongly recommended in a clinical setting where properly trained personnel and equipment for intubation and resuscitation are readily available. 2: Prophylactic surfactant administration is recommended for neonatal respiratory distress syndrome (RDS) in which surfactant deficiency is suspected. 3: Rescue or therapeutic administration of surfactant after the initiation of mechanical ventilation in infants with clinically confirmed RDS is strongly recommended. 4: A multiple surfactant dose strategy is recommended over a single dose strategy. 5: Natural exogenous surfactant preparations are recommended over laboratory derived synthetic suspensions at this time. 6: We suggest that aerosolized delivery of surfactant not be utilized at this time.

AB - We searched the MEDLINE, CINAHL, and Cochrane Library databases for English-language randomized controlled trials, systematic reviews, and articles investigating surfactant replacement therapy published between January 1990 and July 2012. By inspection of titles, references having no relevance to the clinical practice guideline were eliminated. The update of this clinical practice guideline is based on 253 clinical trials and systematic reviews, and 12 articles investigating surfactant replacement therapy. The following recommendations are made following the Grading of Recommendations Assessment, Development, and Evaluation scoring system: 1: Administration of surfactant replacement therapy is strongly recommended in a clinical setting where properly trained personnel and equipment for intubation and resuscitation are readily available. 2: Prophylactic surfactant administration is recommended for neonatal respiratory distress syndrome (RDS) in which surfactant deficiency is suspected. 3: Rescue or therapeutic administration of surfactant after the initiation of mechanical ventilation in infants with clinically confirmed RDS is strongly recommended. 4: A multiple surfactant dose strategy is recommended over a single dose strategy. 5: Natural exogenous surfactant preparations are recommended over laboratory derived synthetic suspensions at this time. 6: We suggest that aerosolized delivery of surfactant not be utilized at this time.

KW - Exogenous surfactant administration

KW - Intratracheal administration

KW - Neonatal respiratory distress syndrome

KW - Prematurity

KW - Surfactant

UR - http://www.scopus.com/inward/record.url?scp=84873617425&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84873617425&partnerID=8YFLogxK

U2 - 10.4187/respcare.02189

DO - 10.4187/respcare.02189

M3 - Article

C2 - 23359726

AN - SCOPUS:84873617425

VL - 58

SP - 367

EP - 375

JO - Respiratory Care

JF - Respiratory Care

SN - 0020-1324

IS - 2

ER -